Ehrenfelt v. Janssen Pharmaceuticals, Inc.

237 F. Supp. 3d 711, 2017 U.S. Dist. LEXIS 135975, 2017 WL 1901737
CourtDistrict Court, W.D. Tennessee
DecidedFebruary 14, 2017
DocketNo. 15-cv-2558-SHL-cgc
StatusPublished

This text of 237 F. Supp. 3d 711 (Ehrenfelt v. Janssen Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, W.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ehrenfelt v. Janssen Pharmaceuticals, Inc., 237 F. Supp. 3d 711, 2017 U.S. Dist. LEXIS 135975, 2017 WL 1901737 (W.D. Tenn. 2017).

Opinion

ORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT

SHERYL H. LIPMAN, UNITED STATES DISTRICT JUDGE

Before the Court are Defendants’ Motion for Summary Judgment (ECF No. 159), filed October 12, 2016, Plaintiffs Response (ECF No. 178), filed November 9, 2016, and Defendant’s Reply (ECF. No. 183), filed November 23, 2016. In addition to arguments attacking the merits - of [713]*713Plaintiffs action, Defendants contend that summary judgment is appropriate because Plaintiffs claims are time:barred by. the applicable statute of limitations and statute of repose. (See ECF No. 159.)

On January 5, 2017, the Court ordered the parties to file additional briefing addressing the narrow issue of whether the strict Kansas statute of repose for personal injury cases, K.S.A. § 60-513(b) (hereinafter, the “general statute of repose”), or the more flexible Kansas Product Liability Act (“KPLA”) statute of repose, K.S.A. § 60-3303(b) (hereinafter, the “KPLA statute of repose”), applies to this action. (ECF No. 187.) As a result, the parties have offered fundamentally opposing interpretations of both the statutes of repose and the relevant Kansas case law, exposing a complex issue of statutory construction. For the following reasons, the Court finds that the Kansas general statute of repose applies to this action, and that Plaintiffs claims are thus time-barred.

I. BACKGROUND

On July 17, 2015, Plaintiff initiated this product liability lawsuit in the Circuit Court of Shelby County, Tennessee, to obtain “damages relating to the Defendants’ design, ‘manufacture, sale, marketing, advertising, promotion, and distribution of Risperdal (risperidone).” (Ex. B, ECF No. 1 at PagelD 25.)1 Specifically,' Plaintiff alleges that his' exposure to Risperdal caused “rapid weight gain, hyperprolac-tinemia, gynecomastia (abnormal development of breasts in males), and galactor-rhea (lactation).” (Id. at PagelD 41.)

Plaintiff began taking Risperdal by approximately October 15, 1997, and he discontinued his initial Risperdal usd on July 1, 1998. (Pl.’s R. to Def.’s Statement of Undisputed Facts, ECF No. 178-2 ¶¶ 1-2.) Later, on February 7, 2000, while hospitalized at St. Catherine Hospital, Plaintiff was again prescribed Risperdal, but he discontinued his second period of Risper-dal use on February 24, 2000. (Id. ¶ 3.) On or about November 29, 2000, Plaintiff was admitted to Larned State Hospital, where he was first .diagnosed with bilateral gyne-comastia. (IdL ¶¶ 12, 14.) Plaintiff , alleges that his gynecomastia was caused by his prior ingestion of Risperdal. (Id. ¶ 17.)

II. ANALYSIS

Based on the undisputed facts in the record, the time of delivery of the allegedly harmful product occurred, at the latest, on October 15, 1997. Likewise, Plaintiffs harm occurred, at the latest, when he first was diagnosed with gynecomastia on November 29, 2000. If the general statute of repose is found to. apply to Plaintiffs claims, this action must be dismissed as untimely. If, by contrast, the KPLA statute of repose applies, the Court then must consider whether Plaintiffs claims qualify under one of the enumerated exceptions in § 3303(b)(2). Because the' Court finds that the general statute of repose applies in this instance, the exceptions are inapposite to Plaintiffs claims.

In determining which statute of repose applies to the present case, the Court must parse the way in which the Kansas Product Liability Act (“KPLA”),:K.S.A, §§ 60-3301 et- seq., fits within the broader body of Kansas tort law. To do so, the Court considers three interconnected, questions. First, applying standard principles of statutory construction, how are the-statutes of repose to be interpreted?-Second, what principles, if any, may be gleaned from a series of Kansas decisions attempting to reconcile the general statute of repose and the KPLA statute of repose? Third,. how much deference should this -Court give to a contradictory Tenth Circuit interpretation of the Kansas statute?

[714]*714A. APPLYING STANDARD PRINCIPLES OF STATUTORY CONSTRUCTION, THE GENERAL STATUTE OF REPOSE, K.S.A. § 60-513(b), APPLIES HERE.

The Court “begin[s] [its] analysis by looking at the language of the statute itself to determine if its meaning is plain.” United States v. Wagner, 382 F.3d 598, 607 (6th Cir. 2004) (quoting United States v. Ninety-Three Firearms, 330 F.3d 414, 420 (6th Cir. 2003)). Determining a statute’s “plain meaning” requires examining “the language and design of the statute as a whole.” United States v. Parrett, 530 F.3d 422, 429 (6th Cir. 2008). In doing so, the Court “gives effect, if possible, to every word [the Kansas legislature] used.” Carcieri v. Salazar, 555 U.S. 379, 391, 129 S.Ct. 1058, 172 L.Ed.2d 791 (2009) (quoting Reiter v. Sonotone Corp., 442 U.S. 330, 339, 99 S.Ct. 2326, 60 L.Ed.2d 931 (1979)).

The plain reading of the Kansas statutory scheme indicates that there are two statutes of repose that could potentially apply to a product liability action, depending on the timing of the alleged harm. First, the KPLA statute of repose is set out in K.S.A. § 60—3303(b)(1), and states that “[i]n claims that involve harm caused more than 10 years after time of delivery, a presumption arises that the harm was caused after the useful safe life had expired.” K.S.A. § 60-3303(b)(2) then carves out various exceptions to that period of repose. Relevant to this case, § 60-3303(b)(2)(B) provides that “[t]he ten-year period of repose established in paragraph (1) of this subsection does not apply if the product- seller intentionally misrepresents facts about its product, or fraudulently conceals information about it, and that conduct was .a substantial cause of the claimant’s harm[,]” and § 60-3303(b)(2)(D) provides that “[t]he ten-year period of repose established in paragraph (1) of this subsection shall not apply if the harm was caused by prolonged exposure to a defective product, or if the injury-causing aspect of the product that existed at the time of delivery was not discoverable by a reasonably prudent person until more than 10 years after the time of delivery, or if the.harm caused within 10 years after the time of-delivery, did not manifest itself until after that time.”

The continuing viability in product liability cases of the second potentially applicable statute, the general statute of repose, is apparent in K.S.A. § 60-3303(c), which provides, “[N]othing contained in subsection (a) and (b) abové shall modify the application of K.S.A.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Reiter v. Sonotone Corp.
442 U.S. 330 (Supreme Court, 1979)
Carcieri v. Salazar
555 U.S. 379 (Supreme Court, 2009)
United States v. Harry Herbert Wagner, Jr.
382 F.3d 598 (Sixth Circuit, 2004)
Patton v. Hutchinson Wil-Rich Manufacturing Co.
861 P.2d 1299 (Supreme Court of Kansas, 1993)
United States v. Parrett
530 F.3d 422 (Sixth Circuit, 2008)
Baumann v. Excel Industries, Inc.
845 P.2d 65 (Court of Appeals of Kansas, 1993)
Harding v. K.C. Wall Products, Inc.
831 P.2d 958 (Supreme Court of Kansas, 1992)
Kerns Ex Rel. Kerns v. G.A.C., Inc.
875 P.2d 949 (Supreme Court of Kansas, 1994)
Willie Curvin v. Carolyn Colvin
778 F.3d 645 (Seventh Circuit, 2015)
Reiter v. Sonotone Corp.
442 U.S. 330 (Supreme Court, 1979)

Cite This Page — Counsel Stack

Bluebook (online)
237 F. Supp. 3d 711, 2017 U.S. Dist. LEXIS 135975, 2017 WL 1901737, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ehrenfelt-v-janssen-pharmaceuticals-inc-tnwd-2017.